Discover
NAMS
NewAmsterdam Pharma Company N.V.
32.34
10 x 30.90
1 x 33.50
bid
ask
+
2.67
9.00%
04:00 PM
| Ytd | -7.81% | |
| 1y | 43.35% |
29.67
day range
32.43
21.14
52 week range
42.20
| Open | 30.37 | Prev Close | 29.67 | Low | 29.67 | High | 32.43 | Mkt Cap | 3.78B |
| Vol | 1.70M | Avg Vol | 1.31M | EPS | -1.59 | P/E | -20.34 | Forward P/E | -27.71 |
| Beta | 0.08 | Short Ratio | 6.98 | Inst. Own | 106.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 33.51 | 200-d Avg | 34.01 | 1yr Est | 49.84 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-05 | 2026-06 | -0.48 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.46 | -0.4 | 0.06 | 13.04% |
| 2026-02-18 | 2025-12 | -0.43 | -0.63 | -0.2 | -45.09% |
| 2025-11-05 | 2025-09 | -0.38 | -0.41 | -0.03 | -7.89% |
| 2025-08-06 | 2025-06 | -0.52 | -0.15 | 0.37 | 71.15% |
| 2025-05-08 | 2025-03 | -0.45 | -0.49 | -0.04 | -8.89% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-30 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-19 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-18 | Needham | Upgrade | Buy | Buy |
| 2026-01-21 | RBC Capital | Upgrade | Outperform | Outperform |
| 2025-12-16 | Stifel | Upgrade | Buy | Buy |
| 2025-12-02 | Goldman Sachs | Upgrade | Neutral | Neutral |
Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-01-06 | AUDET JULIETTE BERANGERE | Officer | 15.10K | Stock Award(Grant) |
| 2026-03-01 | DAVIDSON MICHAEL H | Chief Executive Officer | 174.14K | Sale |
| 2024-12-29 | FORGROWTH NAP B.V. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-01-06 | JONES WILLIAM A JR | Officer | 43.00K | Stock Award(Grant) |
| 2026-03-08 | KASTELEIN JOHANNES JACOB PIETER | Officer and Director | 0.00 | Sale |
| 2025-07-15 | KLING DOUGLAS F | Chief Operating Officer | 44.00K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 16.94M | 0.00 | 14.49% |
| 2026-03-30 | Capital World Investors | 11.11M | 0.00 | 9.50% |
| 2026-03-30 | RA Capital Management, LLC | 9.55M | 0.00 | 8.17% |
| 2026-03-30 | FCPM III SERVICES BV | 9.20M | 0.00 | 7.87% |
| 2026-03-30 | FMR Inc | 8.77M | 0.00 | 7.50% |
| 2026-03-30 | Bain Capital Life Sciences Investors, LLC | 7.31M | 0.00 | 6.25% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | American Funds SMALLCAP World A | 8.40M | 0.00 | 7.18% |
| 2026-03-30 | Vanguard Health Care Inv | 3.95M | 0.00 | 3.38% |
| 2026-03-30 | Capital Group Global Equity Canada F | 2.52M | 0.00 | 2.16% |
| 2026-05-30 | Strategic Advisers Fidelity US TtlStk | 2.01M | 0.00 | 1.72% |
| 2026-05-30 | Polar Capital Biotech S Inc | 1.63M | 0.00 | 1.40% |
| 2026-05-30 | Fidelity Contrafund | 1.58M | 0.00 | 1.36% |